Vaccine

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure...

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...

GC376, the Primary Component of Anivive’s Feline Infectious Peritonitis Drug, Nominated by AVMA and FelineVMA to FDA’s List of Bulk Drug Substance for Compounding Office Stock

Nomination could expedite GC376 availability for veterinariansBlack market FIP treatments shown to be unpredictable and dangerousOther organizations are encouraged to...

error: Content is protected !!